Breast cancer is a disease encompassing a spectrum of molecular subtypes and clinical
presentations, each with distinct prognostic implications and treatment responses. Breast …

Cyclophosphamide (Cy) is a prodrug that is mainly bioactivated by cytochrome P450 (CYP)
2B6 enzyme. Several other enzymes are also involved in its bioactivation and affect its …

Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II–
III triple-negative breast cancer; however, it is largely unknown for which patients ICI without …

The KEYNOTE-522 phase III trial has changed the treatment landscape for patients with
earlystage triple-negative breast cancer (TNBC). 1 Patients with stage II/III TNBC now …

Triple-negative breast carcinoma (TNBC) remains a formidable clinical hurdle owing to its
high aggressiveness and scant therapeutic options. Nonetheless, the evolving landscape of …

PURPOSE The addition of pembrolizumab to chemotherapy in high-risk early triple-negative
breast cancer (TNBC) improves cancer outcomes. However, pembrolizumab induces varied …

Neoadjuvant pembrolizumab plus chemotherapy (P+ CT) has emerged as a standard of
care for stage II-III triple-negative breast cancer (TNBC). However, the best anthracycline …

Simple Summary Breast cancer continues to represent a leading cause of death among
women globally. Recent studies have shown a growing link between breast cancer and the …

Navigating the complex landscape of breast cancer treatment involves distinct strategies for
luminal and triple-negative subtypes. While neoadjuvant chemotherapy historically …

Background Adoption of neoadjuvant chemotherapy (NACT) in the “real world” has been
poorly investigated. Aim of this study was to examine the rate of NACT in Italy, trends over …